bluebird bio’s (BLUE) Hold Rating Reiterated at Oppenheimer

Oppenheimer reissued their hold rating on shares of bluebird bio (NASDAQ:BLUE) in a report published on Tuesday.

A number of other brokerages have also recently commented on BLUE. Maxim Group reiterated a buy rating and issued a $170.00 price target (up from $100.00) on shares of bluebird bio in a research note on Monday, October 9th. Leerink Swann reiterated an outperform rating and issued a $162.00 price target (up from $145.00) on shares of bluebird bio in a research note on Wednesday, November 1st. BMO Capital Markets increased their price target on bluebird bio from $134.00 to $162.00 and gave the company a buy rating in a research note on Monday, October 30th. Jefferies Group reiterated a hold rating and issued a $126.00 price target on shares of bluebird bio in a research note on Wednesday, October 11th. Finally, SunTrust Banks increased their price target on bluebird bio from $108.00 to $163.00 and gave the company a buy rating in a research note on Friday, November 3rd. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. bluebird bio currently has an average rating of Hold and a consensus target price of $157.45.

Shares of bluebird bio (NASDAQ:BLUE) traded down $0.95 on Tuesday, hitting $170.70. The stock had a trading volume of 631,389 shares, compared to its average volume of 1,040,000. bluebird bio has a one year low of $63.10 and a one year high of $222.03. The company has a market cap of $7,820.00, a PE ratio of -24.35 and a beta of 2.08.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The firm had revenue of $7.71 million during the quarter, compared to the consensus estimate of $8.47 million. During the same quarter in the previous year, the company posted ($2.07) earnings per share. The firm’s revenue was up 397.4% on a year-over-year basis. research analysts predict that bluebird bio will post -6.72 EPS for the current year.

In other news, insider David Davidson sold 6,000 shares of the stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $180.30, for a total transaction of $1,081,800.00. Following the transaction, the insider now owns 21,977 shares of the company’s stock, valued at approximately $3,962,453.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Nick Leschly sold 7,050 shares of the stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $145.14, for a total transaction of $1,023,237.00. Following the transaction, the insider now directly owns 259,059 shares in the company, valued at approximately $37,599,823.26. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 222,268 shares of company stock valued at $38,896,707. Company insiders own 3.90% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. boosted its position in shares of bluebird bio by 51.9% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 266,693 shares of the biotechnology company’s stock worth $36,631,000 after purchasing an additional 91,161 shares in the last quarter. Tocqueville Asset Management L.P. boosted its position in shares of bluebird bio by 78.0% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 55,690 shares of the biotechnology company’s stock worth $7,649,000 after purchasing an additional 24,400 shares in the last quarter. Quantitative Investment Management LLC boosted its position in shares of bluebird bio by 1,193.8% during the 2nd quarter. Quantitative Investment Management LLC now owns 104,800 shares of the biotechnology company’s stock worth $11,009,000 after purchasing an additional 96,700 shares in the last quarter. Janus Henderson Group PLC bought a new position in shares of bluebird bio during the 2nd quarter worth about $5,252,000. Finally, California Public Employees Retirement System boosted its position in shares of bluebird bio by 1.5% during the 3rd quarter. California Public Employees Retirement System now owns 86,100 shares of the biotechnology company’s stock worth $11,826,000 after purchasing an additional 1,300 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “bluebird bio’s (BLUE) Hold Rating Reiterated at Oppenheimer” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3136538/bluebird-bios-blue-hold-rating-reiterated-at-oppenheimer.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.